Generic Name and Formulations:
Timolol (as maleate) 0.5%; oph soln; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for ISTALOL:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) once daily in the AM.
Greater than 1st-degree AV block. Overt cardiac failure. Cardiogenic shock. Sinus bradycardia. Bronchial asthma. Severe COPD. History of bronchospasm. Not for use as a sole agent in angle-closure glaucoma.
History of cardiac failure. Discontinue at 1st sign of cardiac failure, and before surgery. Avoid abrupt cessation. Diabetes. May mask hypoglycemia, thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Contact lenses (remove; may reinsert 15 min after instillation). Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid other topical β-blockers. May potentiate systemic β-blockers, reserpine, hypoglycemics, and mydriatic effect of topical epinephrine. May be potentiated by quinidine. May cause conduction defects with digoxin, calcium channel blockers (avoid concomitant use in impaired cardiac function).
Local irritation (burning, stinging), blurred vision, cataract, conjunctival injection, infection, headache, hypertension, itching. Systemic β-blocker effects (eg, bronchospasm, bradycardia, cardiac failure, muscle weakness).
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|